1、【Background of Research and Development】In order to increase the water solubility of posaconazole, sulfobutyl-β-cyclodextrin is used in the preparation of injections at home and abroad. It has been reported in the literature that this excipient has certain hemolytic, renal toxicity and carcinogenicity, and it may also have more serious side effects, which is not known to us, because it should be used more carefully.The pH of Posaconazole injection is about 2-3, which is beyond the tolerance range of human body, and the administration process will stimulate blood vessels greatly, which has potential clinical drug safety risks.

2、【Clinical advantages】HCPO05 is the precursor drug of posaconazole, its water solubility is much higher than posaconazole, in the preparation process does not need to add cosolvent, can be well dissolved in water, so that the number of ingredients in the formula can be reduced in order to reduce the patient may produce side reactions, improve drug safety.Moreover, the pH of the preparation prepared by HCP005 is in the range of human tolerance, reducing vascular irritation and toxic side effects.

3、【Classification】Chemical drug registration 2.1 class

4、【Patent Situation】13.14.18.21

Ⅰ、【Indications】

1.Used to treat a variety of infectious diseases caused by sensitive anaerobic bacteria, including: abdominal infection;Pelvic infection;Oral infection;Surgical infection;Brain infection;Sepsis, bacteremia and other serious anaerobic bacterial infection.

2. It is used for the prevention of infection before surgery and the treatment of anaerobic bacteria infection after surgery.

3. Treat severe amoebiasis of digestive system.

Ⅱ、【Product features 】The latest generation of nitroimidazole drugs, the sodium salt of the L-isomer phosphate derivative of ornidazole, through key technological breakthroughs, the use of unique technology to change the drug properties, its water solubility is better than ornidazole and L-ornidazole, no vascular stimulation, no phlebitis, central nervous system inhibition is less than ornidazole, non-toxic.

Ⅲ、【classification】Chemical drug registration class 1.

Ⅵ、【Patent Situation】1.2.8.17

I、【Indications】

1.Prevention and treatment of deep fungal infections;Treatment of invasive aspergillosis;

2. Treatment of severe invasive infections caused by fluconazol-resistant candida bacteria (including Candida claris);

3. Treatment of severe infections caused by Actinomyces pedis and Fusarium;

4. This product should be used mainly for the treatment of progressive, potentially life-threatening infections in immunodeficient patients (cancer, ICU, surgery, etc.).

II、【Product features】The latest generation of broad-spectrum triazole antifungal drugs.The unique innovative key technologies have made major breakthroughs, and the technical content is at the international leading level.Its high water solubility, no need to add toxic side effects of cosolvents, greatly avoid hemolytic, renal toxicity and carcinogenicity and other adverse reactions;Prolonging the action time of the drug can significantly enhance the antifungal activity and greatly reduce the hepatotoxicity.The toxic side effects were significantly reduced.It can prolong the survival rate of patients while treating severe fungal infection.It will certainly have positive influence and far-reaching significance on clinical treatment.

III、【classification】Chemical drug registration class 1.

IV、【Patent Situation】5.9.10.11.12